- Home
- SNDX vs CMPO Comparison
SNDX vs CMPO Comparison
Compare SNDX & CMPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- CMPO
- Stock Information
- Founded
- SNDX 2005
- CMPO 2000
- Country
- SNDX United States
- CMPO United States
- Employees
- SNDX N/A
- CMPO N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- CMPO Finance: Consumer Services
- Sector
- SNDX Health Care
- CMPO Finance
- Exchange
- SNDX Nasdaq
- CMPO Nasdaq
- Market Cap
- SNDX 1.1B
- CMPO 1.2B
- IPO Year
- SNDX 2016
- CMPO N/A
- Fundamental
- Price
- SNDX $9.00
- CMPO $14.85
- Analyst Decision
- SNDX Strong Buy
- CMPO Strong Buy
- Analyst Count
- SNDX 10
- CMPO 8
- Target Price
- SNDX $35.80
- CMPO $16.19
- AVG Volume (30 Days)
- SNDX 1.8M
- CMPO 825.4K
- Earning Date
- SNDX 07-31-2025
- CMPO 08-06-2025
- Dividend Yield
- SNDX N/A
- CMPO N/A
- EPS Growth
- SNDX N/A
- CMPO N/A
- EPS
- SNDX N/A
- CMPO N/A
- Revenue
- SNDX $43,722,000.00
- CMPO N/A
- Revenue This Year
- SNDX $426.77
- CMPO $7.61
- Revenue Next Year
- SNDX $98.31
- CMPO $8.35
- P/E Ratio
- SNDX N/A
- CMPO N/A
- Revenue Growth
- SNDX N/A
- CMPO N/A
- 52 Week Low
- SNDX $8.58
- CMPO $5.71
- 52 Week High
- SNDX $25.07
- CMPO $14.92
- Technical
- Relative Strength Index (RSI)
- SNDX 38.70
- CMPO 69.38
- Support Level
- SNDX $8.77
- CMPO $13.86
- Resistance Level
- SNDX $9.50
- CMPO $14.56
- Average True Range (ATR)
- SNDX 0.53
- CMPO 0.41
- MACD
- SNDX -0.04
- CMPO -0.01
- Stochastic Oscillator
- SNDX 14.13
- CMPO 94.74
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About CMPO CompoSecure Inc.
CompoSecure Inc is engaged in designing and manufacturing premium financial cards. The Company's metal payment card technology and Arculus security and authentication capabilities deliver premium branded experiences which enable people to access and use their assets, and ensure trust at the point of a transaction. Its products include Metal Cards and Arculus, a digital security platform. It has two reportable segments: Payment Card and Arculus.